Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04526509




Registration number
NCT04526509
Ethics application status
Date submitted
21/08/2020
Date registered
25/08/2020
Date last updated
10/05/2024

Titles & IDs
Public title
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Scientific title
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Secondary ID [1] 0 0
2019-004446-14
Secondary ID [2] 0 0
209012
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neoplasms 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK3901961
Treatment: Drugs - GSK3845097
Treatment: Drugs - GSK4427296
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Fludarabine

Experimental: Substudy 1: Cohort 1 - GSK3901961 in previously treated metastatic NSCLC - Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as intravenous (IV) infusion after completing lymphodepleting chemotherapy.

Experimental: Substudy 1: Cohort 2 - GSK3901961 in previously treated advanced SS or MRCLS - Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as IV infusion after completing lymphodepleting chemotherapy.

Experimental: Substudy 2: GSK3845097 in previously treated advanced SS or MRCLS - Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as IV infusion after completing lymphodepleting chemotherapy.

Experimental: Substudy 3: GSK4427296 in previously treated advanced SS or MRCLS - Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.


Treatment: Drugs: GSK3901961
GSK3901961 as an IV infusion.

Treatment: Drugs: GSK3845097
GSK3845097 as an IV infusion.

Treatment: Drugs: GSK4427296
GSK4427296 as an IV infusion.

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Treatment: Drugs: Fludarabine
Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Enrolled Across Sub Studies
Timepoint [1] 0 0
Day -7

Eligibility
Key inclusion criteria
Eligibility Criteria:

Inclusion criteria:

- Participant must be >=18 years of age and weighs =40 kg on the day of signing informed
consent

- Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles

- Participant's tumor must have tested positive for NY-ESO-1 and/or LAGE-1a expression
by a GSK designated laboratory

- Performance status: Eastern Cooperative Oncology Group of 0-1

- Participant must have adequate organ function and blood cell counts 7 days prior to
leukapheresis

- Participant must have measurable disease according to RECIST v1.1.

Additional criteria for participants with SS/ MRCLS:

- Participant has advanced (metastatic or unresectable) SS or MRCLS confirmed by local
histopathology with evidence of disease-specific translocation

- Participant has completed at least one standard of care (SOC) treatment including
anthracycline containing regimen unless intolerant to or ineligible to receive the
therapy. Participants who are not candidates to receive anthracycline should have
received ifosfamide unless also intolerant to or ineligible to receive ifosfamide.
Participants who received neoadjuvant/adjuvant anthracycline or ifosfamide based
therapy and progressed will be eligible

Additional criteria for participants with non-small cell lung cancer (NSCLC):

- Participant has Stage IV NSCLC as confirmed by histology or cytology

- Prior therapies for participants lacking actionable genetic aberrations (i.e., wild
type), per National Comprehensive Cancer Network (NCCN) guidelines: participant has
been previously treated with or is intolerant to programmed death receptor-1
(PD)-1/Programmed death ligand 1 (PD-L1) checkpoint blockade therapy and has been
previously treated with or is intolerant to a platinum-based chemotherapy. Adjuvant
therapy will count as a regimen if completed within 6 months before relapse. Or for
participants that harbors an actionable genetic aberration (e.g. BRAF, anaplastic
lymphoma kinase [ALK]/ c-ros oncogene 1 [ROS1] etc.), per NCCN guidelines:
participants has been previously treated with or is intolerant to SOC therapy,
including targeted therapy, as recommended by NCCN or equivalent country-level
guidelines (European Society for Medical Oncology [ESMO], National Institute for
Health & Care Excellence [NICE]) . Or Investigator has decided that additional lines
of SOC therapy after the first line are not in the participant's best interest.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Central nervous system (CNS) metastases, with certain exceptions for CNS metastases in
NSCLC as specified in the protocol

- Any other prior malignancy that is not in complete remission

- Clinically significant systemic illness

- Prior or active demyelinating disease

- History of chronic or recurrent (within the last year prior to leukapheresis) severe
autoimmune or immune mediated disease requiring steroids or other immunosuppressive
treatments

- Previous treatment with genetically engineered NY-ESO-1-specific T cells, NY-ESO-1
vaccine or NY-ESO-1 targeting antibody

- Prior gene therapy using an integrating vector

- Previous allogeneic hematopoietic stem cell transplant within the last 5 years or
solid organ transplant

- Washout periods for prior radiotherapy and systemic chemotherapy must be followed

- Major surgery within 4 weeks prior to lymphodepletion

- Pregnant or breastfeeding females

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/06/2023
Sample size
Target
Accrual to date
Final
12
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Canada
State/province [9] 0 0
Ontario
Country [10] 0 0
Canada
State/province [10] 0 0
Quebec
Country [11] 0 0
Germany
State/province [11] 0 0
Bayern
Country [12] 0 0
Germany
State/province [12] 0 0
Nordrhein-Westfalen
Country [13] 0 0
Germany
State/province [13] 0 0
Sachsen
Country [14] 0 0
Netherlands
State/province [14] 0 0
Amsterdam
Country [15] 0 0
Sweden
State/province [15] 0 0
Stockholm

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial will evaluate the safety and efficacy of first time in human engineered T-cell
therapies, in participants with advanced tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04526509
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT04526509